Sat-16-07-2016, 22:22 PM 
		
	
	
		The idea that ldn will never be evaluated for other conditions because it is out of patent has confounding precedents. Thalidomide's resurrection as a treatment for myeloma and DMF's Tecfidera alter ego are examples. There have been evaluations of ldn such as Glasgow 2013 for psoriasis and Ojai Foundation's HIV trial (2008-2010), but there seems to be a paucity of results. A failure to release results does not fill me with optimism.
		
		
		
		
		
		
		
		
	
		
		
			
		
		
	
	
	
	


 Health Boards
Health Boards 
 

 
		
		 
		
		 
				 
				
				
				
				
			
 
		
		
		
		
		
		
		
		
	
		
		
			
		
		
	
